The BPGM Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human A-549 lung carcinoma cell line, offering a loss-of-function model for studying bisphosphoglycerate mutase (BPGM) in a non-erythroid epithelial context. This product consists of a polyclonal pool of cells harboring targeted disruption of the BPGM gene, enabling gene-function analysis without the clonal selection bottleneck. Researchers can use these cells as a flexible tool to interrogate BPGM-dependent metabolic and signaling pathways, with the polyclonal format preserving population-level heterogeneity that may better recapitulate tumor biology. The knockout model provides a stable, ready-to-use platform for experiments requiring BPGM ablation, such as metabolic flux studies, hypoxia response assays, and drug-sensitivity screens.
The A-549 host cell line was originally isolated from the lung adenocarcinoma of a 58-year-old male and displays adherent, type II alveolar epithelial characteristics. It is widely employed as an alveolar basal epithelial cell model in cancer biology, drug metabolism, and respiratory infection research. A-549 cells are particularly valued for in vitro and in vivo oncology studies because they retain key traits of lung adenocarcinoma, including activated KRAS signaling and a partially glycolytic metabolic profile. Their robust growth, ease of culture, and relevance to human lung pathology make them a suitable chassis for assessing the contribution of metabolic enzymes such as BPGM to tumorigenic phenotypes. The unmodified A-549 line already serves as a standard reference in hypoxia- and glycolysis-focused investigations; thus, a BPGM-knockout derivative enables direct comparative studies of pathway perturbation.
BPGM primarily catalyzes the isomerization of 1,3?bisphosphoglycerate to 2,3?bisphosphoglycerate (2,3?BPG) within the Rapoport?CLuebering shunt of glycolysis, representing the main synthetic route for 2,3?BPG, a key allosteric regulator of hemoglobin oxygen affinity. The enzyme also possesses minor phosphoglycerate mutase activity. In the signaling network, BPGM is transcriptionally regulated by GATA1 and KLF1 in erythroid cells, while in non-erythroid contexts its expression can be influenced by hypoxia-inducible factor HIF1A and the oncogene MYC, both of which drive glycolysis. Downstream, BPGM generates 2,3?BPG, which not only modulates hemoglobin oxygen binding but also inhibits phosphoglycerate mutase (PGAM1) and can re-enter glycolytic flux. Representative pathway components include the upstream kinase PGK1 and downstream enzymes ENO1, PKM, and LDHA, alongside cofactors such as heme and the activator 2?phosphoglycolate. Disruption of BPGM therefore eliminates a crucial metabolic shunt, directly reducing 2,3?BPG levels and altering the balance of glycolytic intermediates.
In the A-549 lung cancer model, BPGM knockout is predicted to impair the Rapoport?CLuebering shunt, thereby decreasing 2,3?BPG production and potentially perturbing glycolytic flux and hypoxia adaptation. Since A-549 cells exhibit Warburg effect-like aerobic glycolysis and are responsive to hypoxic stress, loss of BPGM may compromise metabolic flexibility, particularly under low-oxygen conditions encountered in solid tumors. The knockout can be used to dissect non-canonical BPGM functions beyond erythroid 2,3?BPG synthesis??such as its possible contribution to antioxidant defense via pentose phosphate pathway regulation or its influence on nucleotide precursor pools. This model is especially relevant for exploring how cancer cells rewire their central carbon metabolism to support proliferation and survival, and for evaluating whether BPGM represents a metabolic vulnerability in lung adenocarcinoma. The polyclonal nature of the knockout cells also allows researchers to study population-level adaptation to the loss of BPGM, providing insights into compensatory mechanisms.
Typical research applications include investigations into BPGM non?erythroid roles, cancer metabolism and metabolic reprogramming, hypoxic signaling mechanisms, and glycolytic shunt dynamics. The model is suited for a variety of assays, such as Western blotting and RT?qPCR to confirm BPGM ablation and downstream pathway alterations, enzymatic measurement of 2,3?BPG levels, Seahorse metabolic flux analysis to quantify glycolytic and mitochondrial activity, cell proliferation and viability assays under normoxic and hypoxic conditions, transcriptomic profiling by RNA?seq, and metabolomic profiling to map global changes in carbohydrate metabolism. Furthermore, these cells can serve as a platform for drug?target validation in metabolic diseases or for co?culture studies with erythroid progenitors to examine paracrine effects of 2,3?BPG. For additional information about product availability, performance characteristics, or custom services, please contact Ascent Research.
